Separate paper-only DMF holders from suppliers who actually ship. Trade-volume-validated cohort joined to active dossier and inspection class.
Dr Reddy's leads the ticagrelor trade-validated cohort with $7.7M and 50 shipments in 2025, followed by MSN Life Sciences ($3.8M, 96 shipments) and Alkem ($2.6M). Of 46 active Type II DMFs across 38 holders, only 9 distinct suppliers actually shipped under their own name in 2025. The remaining 29 are paper-only at current observability.
| # | Supplier | Country | 2025 export USD | Shipments | Status |
|---|---|---|---|---|---|
| 1 | Dr Reddy's Laboratories | IN · Hyderabad | 50 shipments | $7.7M | NAI |
| 2 | MSN Life Sciences | IN · Hyderabad | 96 shipments | $3.8M | VAI |
| 3 | Alkem Laboratories | IN · Mumbai | 33 shipments | $2.6M | VAI |
| 4 | Teva Women's Health | US · subsidiary | 19 shipments | $2.5M | NAI |
| 5 | Micro Labs | IN · Bengaluru | 47 shipments | $0.95M | NAI |
| 6 | Annora Pharma | IN · Hyderabad | 22 shipments | $0.78M | VAI |
| 7 | USV Private Limited | IN · Mumbai | 24 shipments | $0.65M | VAI |
| 8 | Sun Pharmaceutical Industries | IN · Mumbai | 23 shipments | $0.24M | VAI |
Type the INN. The AI agent pulls every active DMF holder for the molecule from the FDA register.
Each holder is matched against customs export records for the molecule, latest year. Holders with zero shipments are flagged paper-only.
Citation-anchored brief with the real shippers ranked by USD and shipment count, alongside the paper-only segment.
Half a typical DMF cohort shows no current trade. They may be capable but they aren't the priority shortlist for an active RFQ.
Total USD ranks volume, shipment count ranks consistency. A supplier with one $5M shipment is a different risk profile than one with fifty $100K shipments.
Trade-validated supplier is the first filter; clean inspection is the second. The chip shows it inline without an extra query.
Trade declarations refresh weekly. A holder moving from paper-only to active shipper surfaces on the next refresh.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twenty molecules · count of suppliers with non-zero molecule-attributed exports in 2025.
Trade-validated suppliers are the realisable subset of a DMF cohort. PharmaDB joins the regulatory register to molecule-attributed trade aggregates so the list separates paper-only holders from active shippers. The view rests on api_docs joined to company_trade_exports_by_molecule. Refresh cadence is weekly.
Non-zero molecule-attributed exports in the latest trade year, attributed to the supplier's canonical entity. The bar is intentionally low: one observable shipment under the supplier's name puts them in the validated cohort. Volume rank refines from there.
Several reasons. A holder may file dossiers across many molecules but only commercialise a few. A holder may ship via a trader or contract sales channel that hides their identity at customs. A holder may have idle capacity waiting for an RFQ. PharmaDB surfaces the segment so a buyer never confuses dossier coverage with supply availability.
Biologics and biosimilars do not use Type II DMFs. For biosimilar API the validated cohort uses trade and plant attestation as the primary signals. Liraglutide and tirzepatide peptides are covered via the same trade matching.
When a supplier ships through a trader, the trader appears as the named exporter at customs. PharmaDB's `lane_trader_shares` view quantifies trader share per lane; the trade-validated cohort excludes pure-trader entities and surfaces the manufacturer separately when the data permits.
Weekly. Trade aggregates refresh weekly. A holder moving from paper-only to active shipper surfaces on the next refresh; the catalog row carries an as-of timestamp on every result page.
The primary view is API. Companion views for FDF (finished dosage) and intermediates use the same matching but a different molecule-attribution layer. Both are queryable through the AI agent with the same prompt structure.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.